Alpha1-Antitrypsin Deficiency

Rare Disease·MeSH: alpha 1-Antitrypsin Deficiency

Prevalence

30.0 / 100K

5 drugs in development·3 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
alpha-1 15%	Grifols S.A. (GRFS)
fazirsiran	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
fazirsiran	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
fazirsiran	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
liquid alpha1-proteinase inhibitor	Grifols S.A. (GRFS)

BioSniper tracks 5 drugs in development for Alpha1-Antitrypsin Deficiency across 3 companies.

There are 4 clinical trials targeting Alpha1-Antitrypsin Deficiency tracked by BioSniper.

The estimated prevalence of Alpha1-Antitrypsin Deficiency is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.